- Appointment of New Executive Vice President of Supply Chain - - Restructured US Management Board to reflect growth of US operation - Reykjavik, Iceland, 23 February 2007 ? Actavis Group (ICEX: ACT), the international generic pharmaceuticals company, today announces that it has appointed Fearghal Murphy, Executive Vice President of Supply chain and Doug Boothe Executive Vice President of Commercial and Administration in the US. Both will join the Group's Executive board with immediate effect. Fearghal Murphy joined Actavis in 2003 as Group Logistics Manager. He was appointed Supply Chain Director in 2005, and more recently has been Vice president of Purchasing. An Industrial Engineering graduate from the University of Limerick, Ireland, he also holds a master's degree in Engineering. Fearghal, who previously held various supply chain positions in IVAX Pharmaceuticals and Wyeth, will oversee Actavis' global supply chain. He replaces Elin Gabriel who left the Group in January 2007. Doug Boothe joined Actavis in 2005, following the acquisition of Alpharma as Vice President and Chief Operating Officer for Actavis US. Doug will be responsible for all sales and marketing activities in the US market. He holds a BSE in Mechanical & Aerospace Engineering from Princeton University, and a MBA from the Wharton School at the University of Pennsylvania. Actavis also announces that it has restructured its senior management team in the US to reflect the increased scope of its operation in the country. The US management board will now be led by Divya Patel as Executive Chairman of Actavis in the US. It will also comprise of Steinthor Palsson, EVP US Operations, Doug Boothe, recently appointed EVP US Commercial and Administration and Kevin Bain, VP US Financial Operations. Sigurdur Oli Olafsson, currently President of Actavis US will return to Actavis' headquarters in Iceland to take up his recent appointment as Deputy CEO. For further information: Halldor Kristmannsson, VP of Corporate Communications Tel. +354 535 2325/ 840 3425 hkristmannsson@actavis.com About Actavis Group Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in more than 30 countries, with over 11,000 employees. The Company's market capitalization is approximately EUR3n (US$3.8 billion) and it's listed on the Iceland Stock Exchange. Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.